Nutra Pharma Corp (NPHC) 0.0039 $NPHC
Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
M2 - Mon Apr 28, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zbrdd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Vical Incorporated - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Nutra Pharma Corporation - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - Spider Biotech S.r.l. - Kala Pharmaceuticals, Inc. - Coridon Pty Ltd - Sanofi Pasteur SA - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - amenamevir - tenofovir - RPI-78M - RPI-MN - HSV-2 Vaccine - CEL-1000 - HSV Vaccine - HSV-2 Vaccine - C-31-G - MucoCept Platform - HSV-2 Px - NVC-727 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - GV-2207 - MB-66 - Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - BA-368 - HSV-2 Vaccine - RKP-00156 - CEL-1000 - MAb hu2c - HSV Vaccine - Drug For Herpes Simplex Virus - Subunit Vaccine for Herpes Simplex Virus 2 - Small Molecules for Viral Infections - Small Molecules for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/2z...es_simplex
Global Varicella Zoster (HHV-3) Infections Therapeutics Pipeline Review 2014 - Analysis of 8 Companies & 11 Drug Profiles
M2 - Wed Apr 23, 8:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpszts/varicella_zoster) has announced the addition of the "Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Varicella Zoster (HHV-3) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Varicella Zoster (HHV-3) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Novavax, Inc. - SK Chemicals Co., Ltd. - Nutra Pharma Corporation - Green Cross Corporation - Beijing Tiantan Biological Products Co., Ltd. - Epiphany Biosciences, Inc. - Chongqing Zhifei Biological Products Co., Ltd. Drug Profiles - GSK-208136 - RPI-78M - valomaciclovir stearate - Varicella Vaccine - MG-1111 - MMR Varicella Vaccine - Varicella Vaccine - Varicella Zoster Virus Vaccine - Nonimmunosuppressive Cyclosporin Analog Molecule Program - Sattabacin - Second Generation Vaccine For VZV Infection For more information visit http://www.researchandmarkets.com/research/lp...lla_zoster
Nutra Pharma to Seek GSA Certification, Will Market Military Strength Nyloxin to Governmental Agencies and the DoD
Marketwire - Tue Apr 22, 7:31AM CDT
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they are seeking GSA (Government Services Administration) Certification in order to supply a specially formulated Military Strength Nyloxin(R) to the Department of Defense (DoD) and Veterans Affairs Hospitals (VA).
Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating
M2 - Tue Apr 22, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8ckvd2/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating" report to their offering. One of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. Further, the report states that one of the main challenges is the patent expiry of Rilutek. The patent expiry of Rilutek, the only marketed drug for the treatment of ALS, will result in the loss of market exclusivity. Key vendors dominating this space include - Covis Pharmaceutical Inc. - Eisai Co. Ltd. - GlaxoSmithKline plc - Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are - Amorfix Life Sciences Ltd. - BrainStrom Cell Therapeutics Inc. - Newron Pharmaceuticals S.p.A - Neuraltus Pharmaceuticals Inc. - Nutra Pharma Corp. - Oxford BioMedica plc - Pharnext SAS - Q-Therapeutics Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Late Stage Pipeline Snapshot - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/8ckvd2/global
Cyber Kiosk Solutions, Inc. Grows Strategic Advisory Committee Focused on Expansion
PR Newswire - Thu Apr 17, 7:30AM CDT
Cyber Kiosk Solutions, Inc. (OTC Pink: CYBK), hereafter referred to as the "Company" or "CYBK" is pleased to announce that the Company has added DMH International President and CEO, Rik J. Deitsch, to its new Strategic Advisory Committee, formed to help navigate CYBK's expansion into several business verticals. The Company recently named Steven Machat, the head of LegalizePot.us, Inc., the first member of the committee.
Global Amyotrophic Lateral Sclerosis Market 2014-2018: Advanced New Discoveries and Treatments Sheds Light on Factors Involved In ALS
M2 - Thu Feb 13, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/3qv6rf/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018" report to their offering. The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market. Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc. Commenting on the report, an analyst from the team said: The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. According to the report, one of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. For more information visit http://www.researchandmarkets.com/research/3qv6rf/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Myasthenia Gravis - Pipeline Review, H2 2013 Research Report
M2 - Fri Jan 31, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/rz5swx/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H2 2013" report to their offering. 'Myasthenia Gravis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myasthenia Gravis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myasthenia Gravis. Scope - A snapshot of the global therapeutic scenario for Myasthenia Gravis. - A review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myasthenia Gravis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned GlaxoSmithKline plc Grifols, S.A. Astellas Pharma Inc. Nutra Pharma Corporation Alexion Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Cytokinetics, Incorporated HanAll Biopharma Co., Ltd. CuraVac, Inc. Biokine Therapeutics Ltd. Toleranzia AB Varleigh Immuno-Pharmaceuticals Ltd For more information visit http://www.researchandmarkets.com/research/rz...nia_gravis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Nutra Pharma Announces the First Shipments and Product Delivery to MyNyloxin.com Independent Entrepreneurs
Marketwire - Tue Jan 07, 8:34AM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they have begun shipping the initial product orders to MyNyloxin, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel. Nutra Pharma previously announced the launch of the MyNyloxin website that allows for product sales and information as well as allowing distributors to sign up and view the Network Marketing opportunity. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Front Street Energy Growth Fund Inc. Labour Sponsored Fund-Suspension of Redemptions
Marketwire Canada - Fri Dec 20, 1:44PM CST
Due to the 2013 federal government budget announcement that it is discontinuing the Labour Sponsored Venture Capital Corporation ("LSVCC"
program, Front Street Capital 2004 (the "Manager" has announced it is considering options with respect to the labour sponsored fund it manages, Front Street Energy Growth Fund Inc. (the "Fund" .
Nutra Pharma's network marketing distributor partner launches MyNyloxin.com for Nyloxin sales
M2 - Mon Dec 09, 4:45AM CST
Biotechnology company Nutra Pharma Corp (OTCQB:NPHC) announced on Friday that MyNyloxin, a new Network Marketing company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin, in the Network Marketing channel is launching its distributor website at http://www.mynyloxin.com over the coming weekend.
Nutra Pharma Announces the Launch of MyNyloxin.com for Nyloxin Sales Through Their Network Marketing Distributors
Marketwire - Fri Dec 06, 1:23PM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin, a new Network Marketing company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel is launching their distributor website http://www.mynyloxin.com over the coming weekend. The website will allow for product sales and information as well as allowing distributors to sign up and view the Network Marketing opportunity. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Nutra Pharma Corp provides exclusive distribution rights to MyNyloxin for the OTC pain reliever Nyloxin
M2 - Tue Dec 03, 4:31AM CST
Biotechnology company Nutra Pharma Corp (OTCQB:NPHC) stated on Monday that it has granted the exclusive rights to market and distribute its over-the-counter (OTC) pain reliever, Nyloxin, to new Network Marketing company MyNyloxin.
Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin
Marketwire - Mon Dec 02, 7:01AM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin, a new Network Marketing company, will have the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Nutra Pharma to Present at Upcoming Investment Conference
Marketwire - Mon Nov 18, 1:39PM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), will be presenting at the upcoming Undiscovered Equities Conference in Boca Raton, Florida on Thursday, November 21, 2013. The presentation will be made by the Company's CEO, Rik J Deitsch, who will be providing updates on the sales and marketing activities for the Company's over-the-counter (OTC) pain relievers; Nyloxin(R), Pet Pain-Away, Cobroxin(R) and Equine Nyloxin(R).
News and Updates on AXPW, HEMP and NPHC
ACCESSWIRE - Tue Nov 12, 9:30AM CST
News and Updates on Axion Power International Inc. (OTC:AXPW), Hemp Inc (OTC:HEMP) and Nutra Pharma Corporation (OTC:NPHC).
Nutra Pharma Provides Updates for the Marketing of Its All-Natural Pain Reliever, Nyloxin(R)
Marketwire - Mon Nov 11, 7:00AM CST
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that New Vitality, a marketing and distribution company, has begun filming commercials to begin their advertising campaign for the Company's all-natural, non-addictive pain reliever -- Nyloxin(R).
Nutra Pharma Provides Update on Inventory and Fulfillment
Business Wire - Wed Sep 11, 7:30AM CDT
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have completed the process of moving their inventory of their all-natural, non-addictive pain reliever, Nyloxin(R), into their Plantation, Florida facility and that they will be handling fulfillment services in-house.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
M2 - Mon Apr 28, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zbrdd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Vical Incorporated - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Nutra Pharma Corporation - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - Spider Biotech S.r.l. - Kala Pharmaceuticals, Inc. - Coridon Pty Ltd - Sanofi Pasteur SA - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - amenamevir - tenofovir - RPI-78M - RPI-MN - HSV-2 Vaccine - CEL-1000 - HSV Vaccine - HSV-2 Vaccine - C-31-G - MucoCept Platform - HSV-2 Px - NVC-727 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - GV-2207 - MB-66 - Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - BA-368 - HSV-2 Vaccine - RKP-00156 - CEL-1000 - MAb hu2c - HSV Vaccine - Drug For Herpes Simplex Virus - Subunit Vaccine for Herpes Simplex Virus 2 - Small Molecules for Viral Infections - Small Molecules for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/2z...es_simplex
Global Varicella Zoster (HHV-3) Infections Therapeutics Pipeline Review 2014 - Analysis of 8 Companies & 11 Drug Profiles
M2 - Wed Apr 23, 8:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpszts/varicella_zoster) has announced the addition of the "Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Varicella Zoster (HHV-3) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Varicella Zoster (HHV-3) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Novavax, Inc. - SK Chemicals Co., Ltd. - Nutra Pharma Corporation - Green Cross Corporation - Beijing Tiantan Biological Products Co., Ltd. - Epiphany Biosciences, Inc. - Chongqing Zhifei Biological Products Co., Ltd. Drug Profiles - GSK-208136 - RPI-78M - valomaciclovir stearate - Varicella Vaccine - MG-1111 - MMR Varicella Vaccine - Varicella Vaccine - Varicella Zoster Virus Vaccine - Nonimmunosuppressive Cyclosporin Analog Molecule Program - Sattabacin - Second Generation Vaccine For VZV Infection For more information visit http://www.researchandmarkets.com/research/lp...lla_zoster
Nutra Pharma to Seek GSA Certification, Will Market Military Strength Nyloxin to Governmental Agencies and the DoD
Marketwire - Tue Apr 22, 7:31AM CDT
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they are seeking GSA (Government Services Administration) Certification in order to supply a specially formulated Military Strength Nyloxin(R) to the Department of Defense (DoD) and Veterans Affairs Hospitals (VA).
Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating
M2 - Tue Apr 22, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8ckvd2/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating" report to their offering. One of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. Further, the report states that one of the main challenges is the patent expiry of Rilutek. The patent expiry of Rilutek, the only marketed drug for the treatment of ALS, will result in the loss of market exclusivity. Key vendors dominating this space include - Covis Pharmaceutical Inc. - Eisai Co. Ltd. - GlaxoSmithKline plc - Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are - Amorfix Life Sciences Ltd. - BrainStrom Cell Therapeutics Inc. - Newron Pharmaceuticals S.p.A - Neuraltus Pharmaceuticals Inc. - Nutra Pharma Corp. - Oxford BioMedica plc - Pharnext SAS - Q-Therapeutics Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Late Stage Pipeline Snapshot - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/8ckvd2/global
Cyber Kiosk Solutions, Inc. Grows Strategic Advisory Committee Focused on Expansion
PR Newswire - Thu Apr 17, 7:30AM CDT
Cyber Kiosk Solutions, Inc. (OTC Pink: CYBK), hereafter referred to as the "Company" or "CYBK" is pleased to announce that the Company has added DMH International President and CEO, Rik J. Deitsch, to its new Strategic Advisory Committee, formed to help navigate CYBK's expansion into several business verticals. The Company recently named Steven Machat, the head of LegalizePot.us, Inc., the first member of the committee.
Global Amyotrophic Lateral Sclerosis Market 2014-2018: Advanced New Discoveries and Treatments Sheds Light on Factors Involved In ALS
M2 - Thu Feb 13, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/3qv6rf/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018" report to their offering. The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market. Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc. Commenting on the report, an analyst from the team said: The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. According to the report, one of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. For more information visit http://www.researchandmarkets.com/research/3qv6rf/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Myasthenia Gravis - Pipeline Review, H2 2013 Research Report
M2 - Fri Jan 31, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/rz5swx/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H2 2013" report to their offering. 'Myasthenia Gravis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Myasthenia Gravis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myasthenia Gravis. Scope - A snapshot of the global therapeutic scenario for Myasthenia Gravis. - A review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Myasthenia Gravis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned GlaxoSmithKline plc Grifols, S.A. Astellas Pharma Inc. Nutra Pharma Corporation Alexion Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Cytokinetics, Incorporated HanAll Biopharma Co., Ltd. CuraVac, Inc. Biokine Therapeutics Ltd. Toleranzia AB Varleigh Immuno-Pharmaceuticals Ltd For more information visit http://www.researchandmarkets.com/research/rz...nia_gravis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Nutra Pharma Announces the First Shipments and Product Delivery to MyNyloxin.com Independent Entrepreneurs
Marketwire - Tue Jan 07, 8:34AM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they have begun shipping the initial product orders to MyNyloxin, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel. Nutra Pharma previously announced the launch of the MyNyloxin website that allows for product sales and information as well as allowing distributors to sign up and view the Network Marketing opportunity. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Front Street Energy Growth Fund Inc. Labour Sponsored Fund-Suspension of Redemptions
Marketwire Canada - Fri Dec 20, 1:44PM CST
Due to the 2013 federal government budget announcement that it is discontinuing the Labour Sponsored Venture Capital Corporation ("LSVCC"
program, Front Street Capital 2004 (the "Manager" has announced it is considering options with respect to the labour sponsored fund it manages, Front Street Energy Growth Fund Inc. (the "Fund" . Nutra Pharma's network marketing distributor partner launches MyNyloxin.com for Nyloxin sales
M2 - Mon Dec 09, 4:45AM CST
Biotechnology company Nutra Pharma Corp (OTCQB:NPHC) announced on Friday that MyNyloxin, a new Network Marketing company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin, in the Network Marketing channel is launching its distributor website at http://www.mynyloxin.com over the coming weekend.
Nutra Pharma Announces the Launch of MyNyloxin.com for Nyloxin Sales Through Their Network Marketing Distributors
Marketwire - Fri Dec 06, 1:23PM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin, a new Network Marketing company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel is launching their distributor website http://www.mynyloxin.com over the coming weekend. The website will allow for product sales and information as well as allowing distributors to sign up and view the Network Marketing opportunity. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Nutra Pharma Corp provides exclusive distribution rights to MyNyloxin for the OTC pain reliever Nyloxin
M2 - Tue Dec 03, 4:31AM CST
Biotechnology company Nutra Pharma Corp (OTCQB:NPHC) stated on Monday that it has granted the exclusive rights to market and distribute its over-the-counter (OTC) pain reliever, Nyloxin, to new Network Marketing company MyNyloxin.
Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin
Marketwire - Mon Dec 02, 7:01AM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin, a new Network Marketing company, will have the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel. Nutra Pharma will continue to market the products through their retail and Direct Response distributors.
Nutra Pharma to Present at Upcoming Investment Conference
Marketwire - Mon Nov 18, 1:39PM CST
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), will be presenting at the upcoming Undiscovered Equities Conference in Boca Raton, Florida on Thursday, November 21, 2013. The presentation will be made by the Company's CEO, Rik J Deitsch, who will be providing updates on the sales and marketing activities for the Company's over-the-counter (OTC) pain relievers; Nyloxin(R), Pet Pain-Away, Cobroxin(R) and Equine Nyloxin(R).
News and Updates on AXPW, HEMP and NPHC
ACCESSWIRE - Tue Nov 12, 9:30AM CST
News and Updates on Axion Power International Inc. (OTC:AXPW), Hemp Inc (OTC:HEMP) and Nutra Pharma Corporation (OTC:NPHC).
Nutra Pharma Provides Updates for the Marketing of Its All-Natural Pain Reliever, Nyloxin(R)
Marketwire - Mon Nov 11, 7:00AM CST
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that New Vitality, a marketing and distribution company, has begun filming commercials to begin their advertising campaign for the Company's all-natural, non-addictive pain reliever -- Nyloxin(R).
Nutra Pharma Provides Update on Inventory and Fulfillment
Business Wire - Wed Sep 11, 7:30AM CDT
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have completed the process of moving their inventory of their all-natural, non-addictive pain reliever, Nyloxin(R), into their Plantation, Florida facility and that they will be handling fulfillment services in-house.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
